Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO.
The company was incorporated in 2013 and is headquartered in Shanghai, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -0.42 Increased by +40.85% | -0.78 Increased by +46.15% |
| Aug 6, 24 | -0.80 Increased by +36.00% | -0.71 Decreased by -12.68% |
| May 8, 24 | -0.50 Increased by +1.96% | -0.92 Increased by +45.65% |
| Feb 27, 24 | -1.00 Decreased by -53.85% | -0.86 Decreased by -16.28% |
| Nov 7, 23 | -0.71 Increased by +57.74% | -1.04 Increased by +31.73% |
| Aug 7, 23 | -1.25 Increased by +13.19% | -0.79 Decreased by -58.23% |
| May 9, 23 | -0.51 Increased by +43.33% | -0.95 Increased by +46.32% |
| Mar 1, 23 | -0.65 Increased by +70.05% | -1.11 Increased by +41.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 102.27 M Increased by +47.72% | -41.67 M Increased by +39.74% | Decreased by -40.75% Increased by +59.21% |
| Jun 30, 24 | 100.50 M Increased by +45.95% | -80.28 M Increased by +33.60% | Decreased by -79.87% Increased by +54.50% |
| Mar 31, 24 | 87.15 M Increased by +38.78% | -53.47 M Decreased by -85.88% | Decreased by -61.36% Decreased by -33.94% |
| Dec 31, 23 | 65.83 M Increased by +5.16% | -95.43 M Decreased by -263.61% | Decreased by -144.96% Decreased by -245.77% |
| Sep 30, 23 | 69.23 M Increased by +20.31% | -69.15 M Increased by +56.50% | Decreased by -99.89% Increased by +63.84% |
| Jun 30, 23 | 68.86 M Increased by +42.94% | -120.89 M Increased by +11.15% | Decreased by -175.56% Increased by +37.84% |
| Mar 31, 23 | 62.80 M Increased by +34.40% | -28.77 M Increased by +66.08% | Decreased by -45.81% Increased by +74.76% |
| Dec 31, 22 | 62.60 M Increased by +41.72% | -26.25 M Increased by +87.61% | Decreased by -41.92% Increased by +91.26% |